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ABSTRACT 
Objective: To evaluate the efficacy of endorectal Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spet- 
roscopic Imaging (MRSI) combined with total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) 
in selecting candidates for biopsy. Subjects and Methods: 246 patients with elevated tPSA (median: 7.81 ng/ml) un- 
derwent endorectal MRI and MRSI before Transrectal Ultrasound (TRUS) biopsy (10 peripheral + 2 central cores); 
patients with positive biopsies were treated with radical intention; those with negative biopsies were followed up and 
underwent MRSI before each additional biopsy if tPSA rose persistently. Mean follow-up: 27.6 months. We compared 
MRI, MRSI, tPSA, and fPSA with histopathology by sextant and determined the association between the Gleason score 
and MRI and MRSI. We determined the most accurate combination to detect prostate cancer (PCa) using receiver oper-
ating curves; we estimated the odds ratios (OR) and calculated sensitivity, specificity, and positive and negative predic-
tive values. Results: No difference in tPSA was found between patients with and without PCa (p = 0.551). In the pe-
ripheral zone, the risk of PCa increased with MRSI grade; patients with high-grade MRSI had the greatest risk of PCa 
over time (OR = 328.6); the model including MRI, MRSI, tPSA, and fPSA was more accurate (Area under Curve: AUC 
= 95.7%) than MRI alone (AUC = 85.1%) or fPSA alone (AUC = 78.1%), but not than MRSI alone (94.5%). In the 
transitional zone, the model was less accurate (AUC = 84.4%). The association (p = 0.005) between MRSI and Gleason 
score was significant in both zones. Conclusions: MRSI is useful in patients with elevated tPSA. High-grade MRSI 
lesions call for repeated biopsies. Men with negative MRSI may forgo further biopsies because a significantly high 
Gleason lesion is very unlikely. 
 
Keywords: Endorectal MRI; Spectroscopy; Prostate Cancer; Diagnosis; Prostate Specific Antigen (PSA); Free to Total 
PSA Ratio (F/T PSA) 
1. Introduction 
The two most common methods of screening for prostate 
cancer (PCa), digital rectal examination (DRE) and se-
rum total prostate-specific antigen (tPSA) levels, yield 
suboptimal accuracy. The specificity of tPSA is poor for 
levels < 10 ng/ml [1,2]. Thus, 60% to 75% of men with 
tPSA between 4 ng/ml and 10 ng/ml undergo unneces-  
sary biopsies [3]. Moreover, men can have elevated tPSA 
and multiple previous negative biopsies before a diagno- 
sis of PCa is established. The use of %fPSA reduces the 
number of unnecessary biopsies whilst maintaining a 
high PCa detection rate [4,5]. Combined endorectal MRI 
and 3D-MRSI have proven accurate in determining the 
location of PCa [6,7]. We aimed to assess the value of 
endorectal MRI and 3D-MRSI combined with %fPSA to 
select patients for biopsy among men with elevated tPSA 
throughout long-term follow-up. 
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2. Material and Methods 
2.1. Subjects 
Our institutional review board approved this prospective 
study, and all patients provided informed consent. 
We selected 246 patients (median age, 61.0 y; range, 
44 - 77) to undergo endorectal MRI/3D-MRSI before 12- 
core transrectal ultrasound-guided (TRUS) biopsy. Inclu- 
sion criteria were rise in tPSA > 50% or tPSA velocity > 
0.75 ng/ml/year and negative or inconclusive DRE. No 
patients with clear nodules or hardness of the prostate at 
DRE were included. Before entering the study, 3 pa- 
tients had undergone retropubic adenomectomy and 18 
transurethral resection of the prostate (TURP) for symp- 
toms of benign prostatic hyperplasia (BPH), so the tran- 
sition zone was not biopsied in these 21 patients because 
of a lack of visible tissue at TRUS. 
Patients with negative biopsies were followed-up, and 
they underwent MRI/3D-MRSI before each additional 
biopsy (up to 3) if tPSA rose persistently. Patients who 
were found prostate cancer were treated with radical 
treatment (Radical prostatectomy or Radiotherapy) if 
indicated. Variables collected included tPSA level and 
%fPSA.  
2.2. MRI and 3D-MRSI Techniques 
We used a 1.5-T whole-body MRI unit (Signa Horizon 
V.12.0; GE) with a body coil and a phased-array pelvic 
coil together with an expandable endorectal coil (Endo 
ATD Medrad; Warrendale, PA, USA) for signal recap- 
tion. We acquired A) axial T1-weighted sequences of the 
pelvic region and B) axial and coronal high resolution 
T2-weighted fast spin-echo sequences of the prostate and 
seminal vesicles. The 3D-MRSI data were processed and 
aligned with the corresponding MR image on a work- 
station using commercially available software (Functool, 
GE). Peak areas for choline, creatine, and citrate were 
calculated using numeric integration. Metabolic ratio 
maps of [choline + creatine]/citrate ([CC]/Ci) were gen- 
erated.  
The 3D-MRSI datasets were acquired as 16 × 8 × 8 
phase-encoded spectral arrays (1024 voxels) with a spa- 
tial resolution of 0.24 - 0.34 cm³ and 1000 130 . Image 
acquisition took 19 minutes and the entire examination, 
including coil placement, patient positioning, and MRI 
and 3D-MRSI acquisition took 50 to 60 minutes. 
2.3. Image Interpretation 
Three radiologists with extensive experience in MRI and 
3D-MRSI imaging interpretation (12, 6 and 4 years ex-
perience, respectively) evaluated in consensus all MRI 
and MR spectroscopic findings. For tumor localization, 
the prostate was split along the midline and further di-
vided into the apex, middle, and base of the gland (Fig-
ure 1). Thus, the prostate was divided into 6 regions in 
the peripheral zone (PZ) and 2 in the transition zone (TZ). 
Image evaluation consisted of two parts. First, the three 
readers scored the T2-weighted images using a five-point 
scale. The presence of cancer, identified as an area of 
low signal intensity, was recorded for each region. Read-
ers graded their confidence that cancer was present in 
each region on a five-point scale, as follows: grade 1 
indicated definitely no tumor; 2, probably no tumor; 3, 
tumor possible; 4, tumor probable; and 5, tumor defini- 
tely present. Second, all 3D-MRSI data were read inde-
pendently. All the voxels in the 8 regions were evaluated 
and each region was also scored on the five-point scale. 
Mean values of the [CC]/Ci ratio were categorized using 
different scores for the PZ and TZ, according to Kurha- 
newicz et al. [8]. In the PZ, a score of 1 was assigned to 
voxels with [CC]/Ci<0.5; 2 to voxels with 0.5 d [CC]/Ci 
< 0.6; 3 to voxels with 0.6 d [CC]/Ci < 0.7; 4 to voxels 
with 0.7 d [CC]/Ci < 0.8; and 5 to voxels with [CC]/Ci t 
0.8. For the TZ, score 1 was assigned to voxels with a 
[CC]/Ci<0.8; 2 to voxels with 0.8 d [CC]/Ci < 0.9; 3 to 
voxels with 0.9 d [CC]/Ci < 1.0; 4 to voxels with 1.0 d 
[CC]/Ci < 1.1; and 5 to voxels with [CC]/Ci t 1.1. 
2.4. Biopsy 
After standard preparation, all patients underwent TRUS 
biopsy by using a US scanner (Allegra; Siemens, Erlan-
gen, Germany) with a 6.5 MHz sector probe. Twelve 
prostatic cores were obtained using an 18-gauge biopsy 
needle (Bard Urological; Covington, GA, USA) with a 
spring-loaded biopsy gun (Manan Medical Pruducts, 
Northbrook, Ill.). In patients without pathological images 
on MRI/3D-MRSI, 10 cores were obtained from the PZ 
 
 
Figure 1. Schematic representation of the different areas in 
which the prostate was divided (6 in the Peripheral Zone 
and 2 in the Transition Zone) and the cores taken from each 
area in every biopsy. 
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(Sextant biopsy + 4 lateral), and 2 from the TZ (one each 
side) (Figure 1). In patients with pathological images on 
MRI/3D-MRSI, additional cores were obtained from the 
site of the lesion. All cores were labeled according to 
their topographic location. The urologists responsible for 
carrying out the TRUS biopsy (JCB anb RBO) had ex-
tensive experience before this study. 
When the biopsy after MRSI was negative, patients 
were followed up; if PSA kept rising and further biopsies 
were needed, patients underwent MRI/3D-MRSI before 
each biopsy. We performed a maximum of three biopsies 
if PCa was not found. 219 patients underwent a single 
biopsy after MRI/3D-MRSI, 17 patients underwent 2 bio- 
psies, and 10 patients underwent 3 biopsies. 
The material for histopathological evaluation consisted 
of biopsy cores, adenomectomy or TURP specimens from 
treatments performed during the study, and the whole 
gland in patients with PCa who underwent radical pro- 
statectomy (RP). 
2.5. Statistical Analysis 
The PZ and TZ were analyzed separately. The maximum 
values of all readings for MRI and 3D-MRSI were taken 
for analysis in the PZ and in the TZ. We evaluated the 
four predictive variables (MRI, 3D-MRSI (5-point ordi-
nal scales), tPSA, and %fPSA (continuous scales)) sepa-
rately by fitting a binary logistic regression model with 
these variables as predictors. For MRI and 3D-MRSI, we 
considered 3 categories: MRI = 1 - 2 (reference); MRI = 
3; and MRI = 4 - 5. Exceptionally, MRI was split into 2 
categories [MRI = 1 - 2 (reference) and MRI = 3 - 5] in 
the statistical analysis of the TZ because few patients had 
MRI  4.  
Two categories were considered for tPSA:  10 ng/ml 
(reference) and >10 ng/ml and two for fPSA:  15% (ref-
erence) and < 15%, according to Okamura et al. [9].  
We estimated the odds ratio (OR) of each category and 
its accuracy for predicting PCa from the area under re-
ceiver operating characteristic curves (AUC). Sensitivity, 
specificity, positive predictive value (PPV), and negative 
predictive value (NPV) were also calculated. The OR of 
each category was compared with the OR = 1 of the ref-
erence category. The association between Gleason score 
and MRI/3D-MRSI scores was measured by Goodman 
and Kruskal’s gamma coefficient (G). Gleason scores 
were grouped into three categories: up to Gleason 3 + 3; 
from 3 + 4 to 4 + 3; and from 3 + 5 to 5 + 5. We consid-
ered p-values < 0.05 significant. 
3. Results 
Median tPSA was 7.81 n/ml (range: 0.16 - 71.00), and 
median fPSA was 13.08% (range: 0.12% - 41.70%). Me-
dian follow-up was 22.4 months (range: 6 - 81.3 months). 
At the end of the study, 16 patients had undergone 
TURP or adenomectomy for BPH, 29 radical prostatec-
tomy (RP), 25 radiation therapy (RT), and 5 hormone 
therapy (HT). PCa was detected in the PZ (areas 1 to 6) 
in 31.7% (78/246) patients and in the TZ (areas 7 - 8) in 
15.1% (34/225); 82.3% (28/34) of patients with cancer in 
the TZ also had cancer in the PZ. 
3.1. Peripheral Zone  
Mean tPSA in patients with PCa (9.63 ng/ml) was not 
statistically different than in patients without PCa (9.95 
ng/ml) (p = 0.551). The estimated AUC of tPSA as a 
predictive variable was 0.708 (Table 1(A) and Figure 2). 
Mean %fPSA was lower in patients with PCa than in 
those without (12.4% vs. 15.0%; p < 0.001). The estimat- 
ed AUC of %fPSA was 0.781 (Table 1(A) and Figure 2). 
Biopsies were negative in all (29/29) patients with 
grade 1 lesions at MRI and in 86.2% (100/116) of those 
with grade 2 lesions. Biopsies were positive in all (8/8) 
patients with grade 5 lesions at MRI and in 83.3% (10/12) 
of those with grade 4 lesions (Table 2(A)). The AUC of 
MRI was 0.851 (Figure 2). The OR of MRI = 3 and MRI 
= 4 - 5 were 7.9 and 57.4, respectively (Table 1(A)).  
In the analysis of 3D-MRSI, 95.1% (156 164 ) of pati- 
ents with grade 1-2 lesions had negative biopsies and 95.3% 
(41/43) of patients with grade 4-5 3D-MRSI lesions had 
positive biopsies during follow-up (Table 2(A)). Never- 
theless, one of the two patients with grade 4-53D-MRSI 
lesions without cancer in the PZ had a positive biopsy  
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Figure 2. Prostate peripheral zone. Receiver operating cha- 
racteristic (ROC) curves for the predictive variables mag-
netic resonance imaging (MRI), magnetic resonance spec-
troscopy (3D-MRSI), total prostate-specific antigen (tPSA), 
free-to-total prostate-specific antigen ratio (fPSA), and the 
combination of all four variables. The overall accuracy of 
each model is specified in the area under the corresponding 
ROC curves (AUC). 
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Table 1. Odds ratios (OR), area under the receiver operating characteristic curves (AUC), sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV) for the predictors MRI, 3D-MRSI, tPSA, and fPSA of prostate 
cancer in the four individual models and in the multivariate model. Models are adjusted for the number of previous negative 
biopsies and age. 
(A) 
Peripheral zone 
Model OR p-valueb AUC p-valuec Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
Individual predictors 
MRI (5-point scale) 0.851 <0.001 79.5 76.8 61.4 89.0 
MRI = 1,2a 1        
MRI = 3 7.9 <0.001       
MRI = 4,5 57.4 <0.001       
MRSI (5-point scale) 0.945 <0.001 89.7 92.9 85.4 95.1 
MRSI = 1,2a 1        
MRSI = 3 56.6 <0.001       
MRSI = 4,5 328.6 <0.001       
tPSA   0.708 <0.001 47.4 83.3 56.9 77.3 
10 ng/mla 1        
>10 ng/ml 1.4 0.327       
fPSA   0.781 <0.001 64.1 79.8 59.5 82.7 
15%a 1        
<15% 5.6 <0.001       
Multivariate model (all preditors) 0.957  91.0 94.6 88.8 95.8 
(B) 
Transition zone 
Model OR p-valueb AUC p-valuec Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
Individual predictors 
MRI (5-point scale) 0.758 0.061 55.9 82.7 36.5 91.3 
MRI = 1,2a 1        
MRI = 3,4,5 15.9 <0.001       
MRSI (5-point scale) 0.813 0.284 55.9 95.3 67.9 92.4 
MRSI = 1,2a 1        
MRSI = 3 10.1 <0.001       
MRSI = 4,5 56.2 <0.001       
tPSA   0.745 0.042 58.8 80.6 35.1 91.7 
10 ng/mla 1        
>10 ng/ml 4.2 0.001       
fPSA   0.705 <0.001 64.7 63.9 24.2 91.0 
15%a 1        
< 15% 2.1 0.024       
Multivariate model (all preditors) 0.844  76.5 83.2 44.8 95.2 
a.
 
Reference category, b. p-values of the OR compared to the reference category for the corresponding predictor, c. p-values of the AUC compared to the multi-
variate model. 
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Table 2. Biopsy result versus endorectal MRI and 3D-MRSI grades. 
(A) 
Peripheral zone 
MRI grade MRSI grade  
Biopsy result 
1 2 3 4 5 1 2 3 4 5 Total 
Negative (0) 29 100 37 2 0 16 140 10 1 1 168 
Positive (1) 0 16 44 10 8 2 6 29 27 14 78 
Total 29 116 81 12 8 18 146 39 28 15 246 
(B) 
Transitional zone 
MRI grade MRSI grade  
Biopsy result 
1 2 3 4 5 1 2 3 4 5 Total 
Negative (0) 14 172 5 0 0 15 167 7 2 0 191 
Positive (1) 0 22 9 3 0 0 15 6 11 2 34 
Total 14 194 14 3 0 15 182 13 13 2 225 
(C) 
Gleason grades of PCa versus the grade of lesions detected at MRI/3D-MRSI 
 MRI grade MRSI grade    
Gleason grade No of tumors 1 - 2 3 4 - 5 1 - 2 3 4 - 5    
6 (3 + 3) 22 8 11 3 6 7 9    
3 + 4 to 4 + 3 33 9 20 4 5 14 14    
3 + 5 to 5 + 5 29 3 15 11 2 7 20    
Total 84 20 46 18 13 28 43    
G = 0.431, p = 0.001, G = 0.367; p = 0.005. 
 
(Gleason 6: 3 + 3) in the right TZ in the second set of 
biopsies. The second patient had a history of superficial 
bladder cancer treated with BCG 5 years before TRUS 
biopsy, which found granulomas suggestive of tubercu-
losis. The AUC of 3D-MRSI was 0.945 (Figure 2). The 
OR of 3D-MRSI = 3 and 3D-MRSI = 4 - 5 were 56.6 and 
328.6, respectively (Table 1(A)). 
On the combined analysis of MRI-3D-MRSI, 100% 
(17/17) of patients with MRI = 4 - 5 and 3D-MRSI = 4 - 
5 had PCa in the PZ. Four patients with PCa had MRI = 
1 - 2 and 3D-MRSI = 1 - 2; they were found PCa in the 
third set of biopsies and all had a Gleason 6 (3 + 3) PCa 
in a single core at biopsy. The AUC of the model com-
bining all variables (MRI, 3D-MRSI, tPSA, and fPSA) 
was 0.957 (Figure 2), which is significantly greater than 
the AUC of MRI alone, tPSA alone, and fPSA alone, but 
not than the AUC of 3D-MRSI alone (Table 1(A)).  
Table 1(A) summarizes the sensitivity, specificity, and 
predictive values for all individual variables and for the 
multivariate model. Of the individual variables, 3D- 
MRSI had the highest sensitivity (89.7%), specificity 
(92.9%), PPV (85.4%), and NPV (95.1%). Combining all 
variables yielded higher sensitivity (91.0%), specificity 
(94.6%), PPV (88.8%), and NPV (95.8%) than 3D-MRSI 
alone, although differences were not statistically signifi- 
cant. 
3.2. Transition Zone (TZ) 
Among patients with negative biopsies, at MRI 97.4% 
(182/191) had grade 1-2 lesions and none had grade 4-5 
lesions and at 3D-MRSI, 95.3% (182/191) had grade 1 - 
2 lesions, 3.7% (7/191) had grade 3 lesions, 1.1% (2/191) 
had grade 4 lesions, and none had grade 5 lesions. 
Among patients with PCa, at MRI 64.7% (22/34) had 
grade 2 lesions, 35.3% (12/34) had grade 3 or 4 lesions, 
and none had grade 5 lesions and at 3D-MRSI 44.1% 
(15/34) had grade 2 lesions and 55.9% (19/34) had grade 
3 - 5 lesions (Table 2(B)). 
The AUC of MRI and 3D-MRSI were 0.758 and 0.813, 
respectively (Figure 3). OR are summarized in Table 1(B). 
The AUC of the model combining all variables was 
0.844 (Figure 3), which is significantly greater than the 
AUC of tPSA alone or %fPSA alone but not than the  
Copyright © 2012 SciRes.                                                                                  OJU 
J. COMET-BATLLE  ET  AL. 203
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
S
e
n
s
it
iv
it
y
0.00 0.25 0.50 0.75 1.00
1-Specificity
MSI+MRSI+tPSA+fPSA (AUC=0.845)
MRSI (AUC=0.813)
MRI (AUC=0.758)
fPSA (AUC=0.705)
tPSA (AUC=0.745)
No discrimination line
 
Figure 3. Prostate transition zone. Receiver operating char-
acteristic (ROC) curves for the predictive variables mag-
netic resonance imaging (MRI), magnetic resonance spec-
troscopy (3D-MRSI), total prostate-specific antigen (tPSA), 
free-to-total prostate-specific antigen ratio (fPSA), and the 
combination of all four variables. The overall accuracy of 
each model is specified in the area under the corresponding 
ROC curves (AUC). 
 
AUC of MRI alone or 3D-MRSI alone (Table 1(B)).  
The sensitivity (55.9%) and NPV (92.4%) of 3D- 
MRSI were similar to those of the other variables, but its 
specificity (95.3%) and PPV (67.9%) were significantly 
higher. The model combining all variables had a signifi- 
cantly higher sensitivity (76.5%) than MRSI alone, al- 
though its specificity (83.2%) and PPV (44.8%) were sig- 
nificantly lower. The NPV (95.2%) of the combined mo- 
del was similar to that of 3D-MRSI alone (Table 1(B)).  
3.3. Gleason versus MRI and 3D-MRSI 
Table 2(C) shows the relation between MRI/3D-MRSI 
and Gleason score. Both MRI and 3D-MRSI were posi- 
tively associated with the Gleason score (G = 0.431; p = 
0.001 and G = 0.367; p = 0.005, respectively). In patients 
with Gleason  6 (up to 3 + 3), 72.7% (16/22) had high 
grade 3D-MRSI lesions (grade 3-5). In patients with 
Gleason 7 (3 + 4 or 4 + 3), 84.8% (28/33) had high grade 
3D-MRSI lesions, and in patients with Gleason 8-10, 
93.1% (27/29) had grade 3D-MRSI lesions. 
4. Discussion 
Several studies have found benefits from using endorec-
tal MRI and 3D-MRSI in diagnosing and staging PCa 
[7,10]. In a meta-analysis of MRI and 3D-MRSI in the 
diagnosis of PCa, Umbehr et al. [11] concluded that al-
though many studies had encouraging results [12-20], 
larger studies were necessary to confirm its cost-effecti- 
veness. They reported sensitivities and specificities from 
several studies ranging from 58% to 82% and from 78% 
to 91%, respectively, depending on the patient’s risk for 
PCa. In the present study, we found a high sensitivity and 
specificity for MRI/3D-MRSI. Although MRI/3D-MRSI 
was more accurate in the PZ than in the TZ, the accuracy 
in the TZ is still good and is comparable to the accuracy 
reported for other series. This is probably related to the 
presence of experienced radiologists in specialized cen- 
ters.  
D’Amico et al. [21] reported the impact of including 
MRI in a multivariate analysis to predict extraprostatic 
cancer. MRI has also been advocated for planning sur-
gery and deciding whether to resect the neurovascular 
bundle [22]. The European guidelines on PCa state that 
MRI could be accurate in staging PCa and that 3D-MRSI 
increases the accuracy of tumor localization and corre-
lates with the Gleason score [23]. They also suggest us-
ing MRI/3D-MRSI in patients with previous negative 
biopsies with persistent clinical suspicion of PCa [24], 
but the indications are still very vague regarding their use 
for early diagnosis of PCa.  
The rationale behind evaluating the results according 
to the topographic location of PCa comes from the dif-
ferences we observed in the accuracy for the detection of 
PCa depending on the site (TZ or PZ), and our goal was 
to evaluate the usefulness of MRI/3D-MRSI combined 
with clinical parameters in selecting candidates for bi-
opsy according to the risk of having PCa, either in the PZ 
or the TZ. Thus, we focused on whether MRI/3D-MRSI 
is able to avoid biopsies in patients with elevated tPSA. 
In the present study, tPSA ranged from 0.16 ng/ml in a 
patient with a previous adenomectomy with a microfocus 
of PCa in the pathologic specimen to 71.00 ng/ml in an-
other with locally advanced PCa, but the median tPSA 
was relatively low (7.81 ng/ml); nevertheless, tPSA was 
not predictive of PCa. The model incorporating MRI, 
3D-MRSI, and %fPSA was significantly more accurate 
in predicting PCa (AUC = 0.965) than other models us-
ing MRI alone (AUC = 0.857) or %fPSA alone (AUC = 
0.640). In the TZ, the same model was less accurate 
(AUC = 0.845), but this result is still good, considering 
the heterogeneity of the TZ and the low detection rates of 
TRUS biopsy and TURP in the TZ [25,26]. 
Our study has two major limitations: First, is that bi-
opsy results might not be a good representation of the 
real number of patients that have PCa; therefore, the sen-
sitivity of MRI/3D-MRSI measured against this standard 
would lack validity. Nevertheless, this is a detection 
study, and the patients in our series were followed up 
from 6 months to several years, and at least 3 biopsies 
were performed to these patients if no cancer was found, 
to rule out PCa as far as possible. The second one is the 
limited correlation between MRI/3D-MRSI and TRUS, 
Copyright © 2012 SciRes.                                                                                  OJU 
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to ensure that cores were taken from the suspicious MRI 
area. For this reason, when performing the biopsies for 
this study, radiologists and urologists worked together to 
ensure as much as possible the best location of lesions 
detected at MRI/MRSI.  
We confirm the relation between 3D-MRSI and Glea-
son score reported by Zakian et al. [27], who suggested 
the potential of 3D-MRSI for noninvasive assessment of 
PCa aggressiveness.  
We aimed to evaluate the predictive value of MRI/3D- 
MRSI in patients with suspected PCa and to correlate 
MRI/3D-MRSI findings with the clinical and pathologi-
cal findings during long-term follow-up to establish the 
indication for MRI/3D-MRSI in these patients. We sug-
gest patients with the following findings undergo TRUS 
biopsy: 
1) Grade 4 or 5 3D-MRSI. 
2) Grade 3 3D-MRSI and grade 3, 4, or 5 MRI.  
Finally, we are aware that multiparametric MRI has 
the advantages of being quicker and more widely avail-
able [28] than 3D-MRSI, which is time consuming and 
requires special software. However, MRI/3D-MRSI is 
cost-effective because it is less expensive and has similar 
accuracy to diffusion for PCa detection in the PZ and 
may be more accurate than multiparametric MRI in the 
TZ [29]. Thus, MRI/3D-MRSI remains a good tool for 
centers with experience.  
5. Conclusions 
1) In patients with an elevated tPSA and fPSA < 15%, 
suspicious lesions at MRI/3D-MRSI must be biopsied. 
Negative biopsy results call for follow-up including re- 
peat biopsies  
2) In patients without suspicious lesions at 3D-MRSI, 
biopsies for high tPSA might be unnecessary. 
3) Negative MRI/3D-MRSI findings suggest that sig- 
nificant PCa, either in volume or in grade, is unlikely; 
therefore, MRI/3D-MRSI may obviate subsequent biop- 
sies in patients with high PSA or candidates for active 
surveillance.  
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